Crinetics Pharmaceuticals (CRNX) Enterprise Value (2017 - 2026)

Crinetics Pharmaceuticals' Enterprise Value history runs 10 years deep, the most recent figure standing at -$1.3 billion for Q1 2026.

• On a quarterly basis, Enterprise Value fell 1.35% year-over-year to -$1.3 billion in Q1 2026; TTM through Mar 2026 was -$1.3 billion, a 1.35% decrease from a year earlier, with the FY2025 full-year figure at -$1.0 billion, up 24.09% from the prior year.
• Enterprise Value fell to -$1.3 billion in Q1 2026 per CRNX's latest filing, from -$1.0 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$54.2 million in Q2 2025 and bottomed at -$1.4 billion in Q4 2024.
• The 5-year median for Enterprise Value is -$554.7 million (2023), against an average of -$637.9 million.
• Across the five-year window, Enterprise Value plunged 226.22% in 2024 and jumped 93.72% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$334.4 million in 2022, then sank by 67.02% to -$558.6 million in 2023, then plunged by 142.42% to -$1.4 billion in 2024, then advanced by 24.09% to -$1.0 billion in 2025, then retreated by 25.63% to -$1.3 billion in 2026.
• Per Business Quant, the three latest CRNX Enterprise Value figures stand at -$1.3 billion (Q1 2026), -$1.0 billion (Q4 2025), and -$111.4 million (Q3 2025).